Synthesis and secretion of transforming growth factor beta isoforms by primary cultures of human breast tumour fibroblasts in vitro and their modulation by tamoxifen
1996

Tamoxifen and TGF-beta in Breast Tumor Fibroblasts

Sample size: 8 publication Evidence: moderate

Author Information

Author(s): JR Benson, LM Wakefield, M Baum, AA Colletta

Primary Institution: The Royal Marsden Hospital

Hypothesis

Tamoxifen may stimulate fibroblasts to produce transforming growth factor beta (TGF-beta) independently of estrogen receptors.

Conclusion

Tamoxifen increases the synthesis of TGF-beta in breast tumor fibroblasts, but does not consistently enhance its secretion.

Supporting Evidence

  • Tamoxifen treatment did not induce a consistent increase in TGF-beta secretion.
  • Benign breast tumor fibroblasts secreted significantly higher levels of TGF-beta2 compared to malignant fibroblasts.
  • Immunofluorescence showed increased intracellular TGF-beta in tamoxifen-treated fibroblasts.

Takeaway

This study shows that tamoxifen can make certain cells in the breast produce a growth factor that can help control cancer, but it doesn't always help those cells release it.

Methodology

Primary cultures of fibroblasts from malignant and benign breast tumors were treated with tamoxifen, and TGF-beta secretion was measured using immunoassays.

Limitations

The study is based on in vitro data, which may not fully represent in vivo conditions.

Participant Demographics

Fibroblast strains derived from patients with malignant and benign breast tumors, including a strain from normal skin.

Statistical Information

P-Value

p<0.05

Statistical Significance

p<0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication